An integral part of the rheumatology care team, social workers can address specific issues related to a patient’s overall wellbeing. Here are some insights into how rheumatologists can better partner with social workers as part of the interdisciplinary team to ensure better patient outcomes…
Greetings from Washington, D.C., where ACR leaders just held more than 100 meetings on Capitol Hill supporting reforms to step therapy and prior authorization, increased reimbursement for dual-energy X-ray absorptiometry (DXA), solutions to the rheumatology workforce shortage, and rheumatology-specific research at the Pentagon. We’re already hearing great news about our successes: Hours after our visit,…
“Hi, I’m Dr. Kumar, and I’m an allergist,” is something I sometimes fumble when I introduce myself to confused rheumatology patients, before I quickly correct myself with, “… well, I’m also a rheumatologist.” There’s a moment of slight embarrassment that I crossed my circuits, but otherwise I’m proud to say I’m certified in both. This…
Farokh Jamalyaria, MD, a rheumatologist in Houston, never set out to become a birder. He remembers his first foray into birding as being completely unintentional. At 8 years old, while living in Ruston, La., he showed his mother an image of an ivory-billed woodpecker—an extinct species last spotted in the 1940s about 100 miles from…
Paul Sufka Named Social Media Editor for New ACR Twitter Account A clinical rheumatologist with HealthPartners in St. Paul, Minn., Paul Sufka, MD, is conversant with social media: he’s been on Twitter for almost 10 years; has hosted an online rheumatology podcast; and blogs about physician self-care and using Twitter as a tool at medical…
Over the past few years, biosimilars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug option; others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and other medications used to…
Dozens of rheumatology leaders met with more than 100 politicos on Capitol Hill in mid-May, per the ACR’s annual Advocacy Leadership Conference. Armed with research and advocacy training concerning a handful of important issues, rheumatologists, researchers, government affairs specialists and others met with federal lawmakers, legislative aides and correspondents. The two-day conference, which featured the…
A group led by Sarah Ringold, MD, MS, assistant professor of rheumatology at Seattle Children’s Hospital, has developed a new guideline intended to provide recommendations for the treatment and monitoring of children with juvenile idiopathic arthritis (JIA) manifesting as non-systemic polyarthritis, sacroiliitis or enthesitis.1,2 Key Updates The new recommendations appear in both Arthritis & Rheumatology…
(Reuters)—Jacobus Pharmaceutical Co Inc on Monday won U.S. approval for the first drug to treat children with Lambert-Eaton myasthenic syndrome, a rare autoimmune disorder. The drug, Ruzurgi (amifampridine), was approved for use in patients ages 6–17, the according to the U.S. Food and Drug Administration (FDA). Lambert-Eaton myasthenic syndrome (LEMS), which affects about three people…
As soon as pediatric patients are diagnosed with juvenile idiopathic arthritis (JIA), they should also be screened for uveitis, says ophthalmologist Gary Holland, MD. Otherwise, the University of California, Los Angeles, provider says, “Kids who are diagnosed with JIA may not come to an ophthalmologist until they have vision-limiting complications.” Uveitis is the most common…